The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
Well there are no surprises as far as the weather goes! Wet and windy over the next few days. All very autumnal!
There are calls for an inquiry following a 116% rise in patient deaths caused by safety breaches in Welsh NHS hospitals in the last year.
A surge in violent crime and sexual offences has helped push the number of offences recorded by police past five million.